ANALISIS KESESUAIAN BIAYA RIIL PASIEN KANKER PAYUDARA PESERTA JKN NON-PBI DENGAN TARIF INA-CBG’s DI RSUP PROF DR KANDOU MANADO
Abstract
Number of cancer incident in Indonesia exactly in second place that adsorbs state expenditure after hemodialysis included breast cancer. This study aims to find out the suitability of real cost and tariff INA-CBG’s the breast cancer inpatient whom became a member of National Health Insurance (JKN) Non-PBI breast cancer inpatient in RSUP Prof Kandou Manado. The research was an observational study with a cross-sectional design. Data retrospectively collected from medical record inpatient whom registered as a member of National Health Insurance (JKN) Non-PBI during September 2017-August 2018 period and from financial department of RSUP Prof Kandou Manado. Calculating the difference in total real costs with the total tariff of INA-CBG's package in JKN Non-PBI inpatients for breast cancer. The result of the study showed that the cost difference between total real cost and total tariff INA-CBG’s package in chemotherapy patient with C-14-3 code was Rp. 374.645.738, treatment in breast procedure with L-1-50 code was Rp. 496.325.510, and treatment for breast tumor with L-4-11 code was Rp. 294.784.926. The difference value between the real cost and tariff INA-CBG’s package was Rp. 1.165.756.174 for 130 breast cancer patient.
Keywords
Full Text:
PDFReferences
Aisyah, N. 2018. Analisis Biaya Kemoterapi Pada Pasien Rawat Inap Kanker Payudara Peserta JKN di RSUD Ulin Banjarmasin [Tesis]. Yogyakarta: Fakultas Farmasi, Universitas Gadjah Mada.
American cancer society. 2017. Breast cancer. Atlanta, Ga: American cancer society; 2017
Anonim., 2016. Peraturan Menteri Kesehatan Nomor 52 Tahun 2016 Tentang Standar Tarif Pelayanan Kesehatan dalam Penyelenggaraan Program Jaminan Kesehatan. Menteri Kesehatan Republik Indonesia, Jakarta.
Kemenkes. 2016. Bulan Peduli Kanker Payudara. Pusat Data dan Informasi Kementerian Kesehatan RI (Infodatin). 2446-7659.
Kemenkes. 2017. Pedoman Nasional Pelayanan Kedokteran: Kanker Payudara. Komite Penanggulangan Kanker Nasional: Kemenkes RI.
Purnamasari V, Andayani TM, Fudholi A. 2015. Analisis biaya terapi pada pasien Kanker Payudara dengan terapi Hormon di RSUP Dr. Wahidin Sudirohusodo Makassar Sulawesi Selatan. Jurnal Manajemen dan Pelayanan Farmasi 5(1):1-7
Sari, TH. 2017. Hubungan antara self compassion dan regulasi emosi dengan stres pada pasien kanker payudara pasca operasi yang sedang menjalani kemoterapi di rsu. Dadi keluarga purwokerto [Tesis]. Purwokerto: Fakultas Psikologi, Universitas Muhammadiyah Purwokerto.
Harianto, Andayani TM, Herowati R. 2015. Komparasi Biaya Riil Dengan Tarif INA CBGs dan Analisis Faktor yang Mempengaruhi Biaya Riil Kemoterapi Pada Pasien Kanker Payudara Rawat Inap Jamkesmas di RSUP Dr Sardjito Yogyakarta. dalam: Prosiding Seminar Fakultas Farmasi Universitas Setia Budi dipresentasikan pada Seminar Farmasi, 11 April 2015 07:02. Surakarta: 1/1.
Manawan, Fridly. 2019. Cost of Illnes Pasien Kanker Payudara di Rumah Sakit Umum Prof DR R.D Kandou Manado [Tesis]. Surakarta: Fakultas Farmasi, Universitas Setia Budi Surakarta.
Thabrany, H. 2011. Diskusi Penatalaksanaan dan Pembiayaan Kanker di Indonesia ; FKM-UI dan Roche Indonesia. Jakarta, 11 Mei 2011.
Rondonuwu IA, Haroen H, Wantania FE. 2016. Profil Kanker Payudara di RSUP Prof. Dr. R.D. Kandou Manado tahun 2013-2014. Jurnal e-Clinic (eCl) Volume 4 No 1, Januari-Juni 2016.
Tfayli A, Temraz S, Mrad RA, Shamseddine A. 2010. Breast Cancer In Low-And Middle-Income Countries : An Emerging And Challenging Epidemic. Journal of oncology Vol 490631, 5.
Vydelingum, NA. 2004. Economic Costs of Cancer Health Disparities In E. Taylor, ed Economic Costs of Cancer Health Disparities. US Departement of Health and Human Services.
DOI: https://doi.org/10.35799/pha.11.2022.40472
Refbacks
- There are currently no refbacks.
Copyright (c) 2022 PHARMACON
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Publisher : | Cooperation With : |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.